Wegovy will be covered by some insurers, but not for weight loss: report
By Tomi Kilgore
WSJ report says CVS, Elevance and Kaiser Permanente will cover Wegovy for some on Medicare with heart conditions
Some large health insurers in the U.S. will start covering Wegovy, which has become a popular anti-obesity drug - but not for those using it to lose weight, according to a report by The Wall Street Journal.
The WSJ report said CVS Health Corp. (CVS), Elevance Health Inc. (ELV) and Kaiser Permanente will start covering the drug, made by Denmark-based Novo Nordisk A/S (NVO) (DK:NOVO.B), but only for people with heart disease, who are covered by a Medicare drug-benefit plan who have heart disease and are using Wegovy to reduce risks of heart attacks and strokes.
The U.S.-listed shares of Novo Nordisk rose 0.5% in morning trading. It has gained 7.4% so far in March, and has run up 41.4% amid a six-month win streak.
Elevance, which runs many Blue Cross and Blue Shield plans, said it would also extend coverage to those insured by commercial plans, the WSJ report said.
The news comes a week after the Centers for Medicare and Medicaid Services said it would start covering Wegovy for older adults if they are using it to treat serious heart disease.
Also read: Wegovy gets FDA approval to reduce risk of heart issues in overweight adults.
Any help from insurers will be welcomed by those who need Wegovy, as the drug costs roughly $1,100 to $1,300 a month.
But there remains a debate in Congress over what should and shouldn't be covered, as Medicare coverage of the expensive drug could inflate the federal deficit.
Eleanor Laise contributed to this article.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-28-24 0955ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing